Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free KROS Stock Alerts $46.87 +0.56 (+1.21%) (As of 05/31/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 5EstimatedActual EPS (May. 8) -$1.21 Beat By $0.12 Consensus EPS (May. 8) -$1.33 Latest SEC 10-Q Filing Get Keros Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for KROS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin AnalyticsBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($1.34)($1.22)($1.26)Q2 20244($1.40)($1.15)($1.24)Q3 20244($1.47)($1.16)($1.28)Q4 20244($1.27)($0.71)($1.09)FY 202416($5.48)($4.24)($4.87)Q1 20251($1.17)($1.17)($1.17)Q2 20251($1.18)($1.18)($1.18)Q3 20251($1.02)($1.02)($1.02)Q4 20251($0.80)($0.80)($0.80)FY 20254($4.17)($4.17)($4.17)KROS Earnings Date and InformationKeros Therapeutics last released its quarterly earnings data on May 8th, 2024. The reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.12. The company had revenue of $0.08 million for the quarter. Its quarterly revenue was down 97.3% on a year-over-year basis. Keros Therapeutics has generated ($5.15) earnings per share over the last year (($5.15) diluted earnings per share). Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.97) to ($5.46) per share. Keros Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based off prior year's report dates.Read More Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/5/2024(Estimated)------- 5/8/2024Q1 2024($1.33)($1.21)+$0.12($1.21)-$0.08 million 3/1/2024Q4 2023($1.37)($1.34)+$0.03($1.34)-$0.14 million11/6/2023Q3 2023($1.35)($1.33)+$0.02($1.33)-$0.01 million 8/7/2023Q2 2023($1.34)($1.27)+$0.07($1.27)$0.22 million- 5/4/2023Q1 2023($1.14)($1.26)($0.12)($1.26)$0.22 million-3/3/2023Q4 2022($1.12)($1.09)+$0.03($1.09)-- Get the Latest News and Ratings for KROS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/3/2022Q3 2022($1.26)($0.92)+$0.34($0.92)--8/4/2022Q2 2022($1.07)($1.13)($0.06)($1.13)--5/5/2022Q1 2022($0.86)($1.01)($0.15)($1.01)$4.50 million- 3/9/2022Q4 2021($0.94)($0.30)+$0.64($0.30)-$20.00 million11/4/2021Q3 2021($0.72)($0.87)($0.15)($0.87)--8/5/2021Q2 2021($0.66)($0.67)($0.01)($0.67)-$0.10 million5/6/2021Q1 2021($0.58)($0.68)($0.10)($0.68)-- 3/24/2021Q4 2020($0.57)($0.49)+$0.08($0.49)--11/10/2020Q3 2020($0.60)($0.60)-($0.60)--8/13/2020Q2($0.6750)($0.62)+$0.0550($0.62)--5/22/2020Q1 2020($0.37)($5.11)($4.74)($5.11)-- Keros Therapeutics Earnings - Frequently Asked Questions When is Keros Therapeutics's earnings date? Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based off last year's report dates. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) reported ($1.21) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.33) by $0.12. Learn more on analysts' earnings estimate vs. KROS's actual earnings. How can I view Keros Therapeutics's earnings report? Keros Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $150,000.00. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.15 earnings per share over the last four quarters. What is Keros Therapeutics's EPS forecast for next year? Keros Therapeutics's earnings are expected to decrease from ($4.97) per share to ($5.46) per share in the next year. More Earnings Resources from MarketBeat Related Companies: SRRK Earnings YMAB Earnings AMRN Earnings FGEN Earnings ITCI Earnings JAZZ Earnings BPMC Earnings IONS Earnings OGN Earnings BBIO Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Hormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New HeightsTD Bank Q2 Earnings: Record Highs and Regulatory HurdlesPDD Holdings Earnings Volatility Alerts Buyers Zoom Stock’s Earnings Volatility Picked Up a Lot of BuyersBaidu Stock Earnings Prove Ray Dalio Right about China? This page (NASDAQ:KROS) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWho are Nvidia’s New Silent Partners?Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin Analytics41 banks launch ‘crypto dollar’Stansberry ResearchGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
